- Home
- CYTK vs BBIO Comparison
CYTK vs BBIO Comparison
Compare CYTK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- BBIO
- Stock Information
- Founded
- CYTK 1997
- BBIO 2015
- Country
- CYTK United States
- BBIO United States
- Employees
- CYTK N/A
- BBIO N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CYTK Health Care
- BBIO Health Care
- Exchange
- CYTK Nasdaq
- BBIO Nasdaq
- Market Cap
- CYTK 5.7B
- BBIO 5.6B
- IPO Year
- CYTK 2004
- BBIO 2019
- Fundamental
- Price
- CYTK $45.82
- BBIO $36.08
- Analyst Decision
- CYTK Buy
- BBIO Strong Buy
- Analyst Count
- CYTK 15
- BBIO 13
- Target Price
- CYTK $83.64
- BBIO $48.33
- AVG Volume (30 Days)
- CYTK 1.1M
- BBIO 2.5M
- Earning Date
- CYTK 02-25-2025
- BBIO 02-20-2025
- Dividend Yield
- CYTK N/A
- BBIO N/A
- EPS Growth
- CYTK N/A
- BBIO N/A
- EPS
- CYTK N/A
- BBIO N/A
- Revenue
- CYTK $3,219,000.00
- BBIO $217,765,000.00
- Revenue This Year
- CYTK N/A
- BBIO $2,309.33
- Revenue Next Year
- CYTK $710.83
- BBIO N/A
- P/E Ratio
- CYTK N/A
- BBIO N/A
- Revenue Growth
- CYTK N/A
- BBIO 2209.77
- 52 Week Low
- CYTK $44.49
- BBIO $21.62
- 52 Week High
- CYTK $84.92
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- CYTK 39.27
- BBIO 73.73
- Support Level
- CYTK $44.49
- BBIO $33.73
- Resistance Level
- CYTK $48.45
- BBIO $36.24
- Average True Range (ATR)
- CYTK 1.65
- BBIO 1.63
- MACD
- CYTK -0.08
- BBIO 0.65
- Stochastic Oscillator
- CYTK 23.50
- BBIO 97.63
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.